• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

西妥昔单抗会影响副肿瘤性肌病吗？

Can cetuximab affect paraneoplastic myopathy?

作者信息

Galani Eleni, Bonakis Anastasios, Christodoulou Christos, Klouvas George, Drougou Angeliki, Skarlos Dimostenis

机构信息

Second Oncology Department, Metropolitan Hospital, Athens, Greece.

出版信息

J Neurooncol. 2009 Jul;93(3):437-8. doi: 10.1007/s11060-009-9795-6. Epub 2009 Jan 22.

DOI:10.1007/s11060-009-9795-6
PMID:19159079
Abstract

Cetuximab given concurrently with chemotherapy has shown survival benefit for patients with metastatic colon cancer. We report a case of a patient with metastatic colon cancer who developed paraneoplastic necrotizing myopathy that possibly responded to cetuximab despite lack of improvement of the underlying cancer.

摘要

西妥昔单抗与化疗同时使用已显示出对转移性结肠癌患者有生存益处。我们报告了一例转移性结肠癌患者，该患者发生了副肿瘤性坏死性肌病，尽管基础癌症未改善，但该患者可能对西妥昔单抗有反应。

相似文献

1
Can cetuximab affect paraneoplastic myopathy?西妥昔单抗会影响副肿瘤性肌病吗？
J Neurooncol. 2009 Jul;93(3):437-8. doi: 10.1007/s11060-009-9795-6. Epub 2009 Jan 22.
2
Successful and well-tolerated second line therapy with cetuximab, irinotecan, and raltitrexed in progressive liver disease due to metastatic colon cancer.西妥昔单抗、伊立替康和雷替曲塞用于转移性结肠癌所致进行性肝病的二线治疗成功且耐受性良好。
J Gastrointest Cancer. 2008;39(1-4):26-8. doi: 10.1007/s12029-009-9060-4. Epub 2009 May 6.
3
Bevacizumab in combination with cetuximab and irinotecan after failure of cetuximab and irinotecan in patients with metastatic colorectal cancer.贝伐珠单抗联合西妥昔单抗和伊立替康治疗转移性结直肠癌患者在西妥昔单抗和伊立替康治疗失败后的应用。
Acta Oncol. 2011 May;50(4):574-7. doi: 10.3109/0284186X.2010.546369.
4
[Efficacy of cetuximab combined with chemotherapy for patients with advanced colorectal cancer and unclear K-ras status].西妥昔单抗联合化疗治疗K-ras状态不明的晚期结直肠癌患者的疗效
Zhonghua Zhong Liu Za Zhi. 2010 Oct;32(10):777-81.
5
Epidermal growth factor receptor inhibition induces trichomegaly.表皮生长因子受体抑制可诱导毛发增大。
Acta Oncol. 2003;42(4):345-6. doi: 10.1080/02841860310006038.
6
[A review of chemotherapy for metastatic colon cancer].[转移性结肠癌化疗综述]
Farm Hosp. 2006 Nov-Dec;30(6):359-69. doi: 10.1016/s1130-6343(06)74007-7.
7
Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study.西妥昔单抗、贝伐单抗和伊立替康与单独使用西妥昔单抗和贝伐单抗治疗伊立替康难治性结直肠癌的随机II期试验：BOND-2研究
J Clin Oncol. 2007 Oct 10;25(29):4557-61. doi: 10.1200/JCO.2007.12.0949. Epub 2007 Sep 17.
8
Treatment with cetuximab, bevacizumab and irinotecan in heavily pretreated patients with metastasized colorectal cancer.在接受过大量治疗的转移性结直肠癌患者中使用西妥昔单抗、贝伐单抗和伊立替康进行治疗。
Anticancer Res. 2008 Nov-Dec;28(6B):4111-5.
9
Reversible grade 4 hyperbilirubinemia in a patient with UGT1A1 7/7 genotype treated with irinotecan and cetuximab.一名携带UGT1A1 7/7基因型的患者在接受伊立替康和西妥昔单抗治疗后出现可逆性4级高胆红素血症。
Clin Colorectal Cancer. 2007 Mar;6(6):447-9. doi: 10.3816/CCC.2007.n.015.
10
Current stages of adjuvant treatment of colon cancer.结肠癌辅助治疗的当前阶段
Ann Oncol. 2012 Sep;23 Suppl 10:x71-6. doi: 10.1093/annonc/mds354.

引用本文的文献

1
Paraneoplastic Necrotizing Autoimmune Myopathy in a Patient Undergoing Laparoscopic Pancreatoduodenectomy for Distal Cholangiocarcinoma.一名因远端胆管癌接受腹腔镜胰十二指肠切除术患者的副肿瘤性坏死性自身免疫性肌病
Case Rep Gastroenterol. 2016 Oct 6;10(3):525-530. doi: 10.1159/000448882. eCollection 2016 Sep-Dec.
2
Immune-Mediated Necrotizing Myopathy: Update on Diagnosis and Management.免疫介导性坏死性肌病：诊断与管理的最新进展
Curr Rheumatol Rep. 2015 Dec;17(12):72. doi: 10.1007/s11926-015-0548-6.
3
Paraneoplastic Necrotizing Myopathy with a Mild Inflammatory Component: A Case Report and Review of the Literature.

本文引用的文献

1
Paraneoplastic myopathy: response to intravenous immunoglobulin.副肿瘤性肌病：静脉注射免疫球蛋白的疗效
Neuromuscul Disord. 2007 May;17(5):404-8. doi: 10.1016/j.nmd.2007.01.004. Epub 2007 Mar 1.
2
Epidermal growth factor induces vasoconstriction through the phosphatidylinositol 3-kinase-mediated mitogen-activated protein kinase pathway in hypertensive rats.表皮生长因子通过磷脂酰肌醇3激酶介导的丝裂原活化蛋白激酶途径诱导高血压大鼠血管收缩。
J Pharmacol Sci. 2006 Jun;101(2):135-43. doi: 10.1254/jphs.fp0060021. Epub 2006 Jun 10.
3
Role of antibody-dependent cell-mediated cytotoxicity in the efficacy of therapeutic anti-cancer monoclonal antibodies.
伴有轻度炎症成分的副肿瘤性坏死性肌病：一例报告并文献复习
Case Rep Oncol. 2010 Apr 8;3(1):88-92. doi: 10.1159/000308714.
抗体依赖性细胞介导的细胞毒性在治疗性抗癌单克隆抗体疗效中的作用。
Cancer Metastasis Rev. 2005 Dec;24(4):487-99. doi: 10.1007/s10555-005-6192-2.
4
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.西妥昔单抗单药治疗及西妥昔单抗联合伊立替康治疗伊立替康难治性转移性结直肠癌。
N Engl J Med. 2004 Jul 22;351(4):337-45. doi: 10.1056/NEJMoa033025.
5
Epidermal growth factor: a potent vasoconstrictor in experimental hypertension.表皮生长因子：实验性高血压中的一种强效血管收缩剂。
Am J Physiol. 1999 Mar;276(3):H976-83. doi: 10.1152/ajpheart.1999.276.3.H976.
6
Paraneoplastic necrotizing myopathy: clinical and pathological features.副肿瘤性坏死性肌病：临床与病理特征
Neurology. 1998 Mar;50(3):764-7. doi: 10.1212/wnl.50.3.764.